Almac Diagnostic Collaborates with Queen’s University to Bring Personalized Chemotherapy for Esophageal Cancer
Shots:
- Almac Diagnostic and Queen’s University validate a test to decide the chemotherapy to be used for early-stage esophageal cancer to remove the tumor, improve prognosis and QoL
- The focus of the collaboration is to bring personalized therapies for esophageal cancer. Additionally, Almac Diagnostic has developed DNA Damage Immune Response (DDIR) Signature to personalize chemotherapy for breast cancer
- The test increases the molecular understanding of each patient’s cancer and enables the clinicians to decide the right chemotherapy to shrink the tumor
Click here to read full press release/ article | Ref: Almac Diagnostic | Image: Glassdoor